Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.
Fletcher RA, Herrington WG, Agarwal R, Mayne KJ, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Staplin N, Wheeler DC, Chertow GM, Heerspink HJL, Neuen BL. Fletcher RA, et al. Among authors: arnott c. Clin J Am Soc Nephrol. 2024 Apr 16. doi: 10.2215/CJN.0000000000000470. Online ahead of print. Clin J Am Soc Nephrol. 2024. PMID: 38622766
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease.
Waijer SW, Sen T, Arnott C, Neal B, Kosterink JGW, Mahaffey KW, Parikh CR, de Zeeuw D, Perkovic V, Neuen BL, Coca SG, Hansen MK, Gansevoort RT, Heerspink HJL. Waijer SW, et al. Among authors: arnott c. Clin J Am Soc Nephrol. 2022 Feb;17(2):251-259. doi: 10.2215/CJN.08780621. Epub 2021 Dec 7. Clin J Am Soc Nephrol. 2022. PMID: 34876454 Free PMC article. Clinical Trial.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
Fletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL. Fletcher RA, et al. Among authors: arnott c. J Am Soc Nephrol. 2023 Dec 1;34(12):1965-1975. doi: 10.1681/ASN.0000000000000248. Epub 2023 Oct 25. J Am Soc Nephrol. 2023. PMID: 37876229
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ. Neuen BL, et al. Among authors: arnott c. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5. Lancet Diabetes Endocrinol. 2019. PMID: 31495651
Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
Shaman AM, Smyth B, Arnott C, Palmer SC, Mihailidou AS, Jardine MJ, Gallagher MP, Perkovic V, Jun M. Shaman AM, et al. Among authors: arnott c. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1129-1138. doi: 10.2215/CJN.12201019. Epub 2020 Jul 16. Clin J Am Soc Nephrol. 2020. PMID: 32675281 Free PMC article.
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Yu J, Zhou Z, Mahaffey KW, Matthews DR, Neuen BL, Heerspink HJL, Jardine MJ, Li J, Perkovic V, Neal B, Arnott C. Yu J, et al. Among authors: arnott c. Int J Cardiol. 2021 Feb 1;324:165-172. doi: 10.1016/j.ijcard.2020.09.050. Epub 2020 Sep 24. Int J Cardiol. 2021. PMID: 32979427
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Neuen BL, Arnott C, Perkovic V, Figtree G, de Zeeuw D, Fulcher G, Jun M, Jardine MJ, Zoungas S, Pollock C, Mahaffey KW, Neal B, Heerspink HJL. Neuen BL, et al. Among authors: arnott c. Diabetes Obes Metab. 2021 Feb;23(2):382-390. doi: 10.1111/dom.14226. Epub 2020 Oct 29. Diabetes Obes Metab. 2021. PMID: 33043620 Free PMC article.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE, Arnott C, Chang TI, Górriz JL, Cannon CP, Charytan DM, de Zeeuw D, Levin A, Mahaffey KW, Neal B, Pollock C, Wheeler DC, Luca Di Tanna G, Cheng H, Perkovic V, Neuen BL. Ye N, et al. Among authors: arnott c. Circulation. 2021 May 4;143(18):1735-1749. doi: 10.1161/CIRCULATIONAHA.120.048740. Epub 2021 Feb 8. Circulation. 2021. PMID: 33554616
126 results